Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.
Diabetic nephropathy
glucagon-like peptide-1
glucagon-like peptide-1 receptor agonist
hyperglycaemia
obesity
paediatrics
type 2 diabetes
Journal
TouchREVIEWS in endocrinology
ISSN: 2752-5457
Titre abrégé: touchREV Endocrinol
Pays: England
ID NLM: 101779126
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
18
01
2023
accepted:
20
04
2023
medline:
14
6
2023
pubmed:
14
6
2023
entrez:
14
6
2023
Statut:
ppublish
Résumé
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained traction for the management of type 2 diabetes and obesity. Unlike several classes of antidiabetic medications that contribute to weight gain, GLP-1RAs not only reduce haemoglobin A1c, but also promote weight loss. While there is a large body of evidence supporting its safety and efficacy in adults, paediatric clinical trial data have only emerged in recent years. This review will discuss the limited treatment options for paediatric type 2 diabetes and the mechanism of action of GLP-1RAs as it pertains to physiological pathways relevant for type 2 diabetes, obesity and their related comorbidities. The outcomes of paediatric trials evaluating liraglutide, exenatide, semaglutide and dulaglutide in paediatric type 2 diabetes and obesity will be closely examined, including differences compared with adult studies. Finally, potential barriers and strategies to expanding GLP-1RA access in adolescents will be discussed. Future studies are needed to determine if the cardio-and renal-protective benefits of GLP-1RAs apply to youth-onset type 2 diabetes.
Identifiants
pubmed: 37313232
doi: 10.17925/EE.2023.19.1.38
pmc: PMC10258616
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
38-45Informations de copyright
© Touch Medical Media 2023.
Déclaration de conflit d'intérêts
Disclosures: LCC was a site-i nvestigator for the AWARDPEDS clinical trial. CB and APV have no financial or nonfinancial relationships or activities to declare in relation to this article.
Références
Cell Metab. 2010 Jun 9;11(6):543-553
pubmed: 20519125
Cell Metab. 2014 Jun 3;19(6):1050-7
pubmed: 24836562
Cell Metab. 2018 Apr 3;27(4):740-756
pubmed: 29617641
Diabetes Care. 2016 Sep;39(9):1635-42
pubmed: 27486237
J Clin Pharm Ther. 2022 Feb;47(2):184-193
pubmed: 34964141
Diabetes Care. 2018 Aug;41(8):1560-1562
pubmed: 29941499
Pediatr Diabetes. 2021 Sep;22(6):872-875
pubmed: 34018306
Diabetes Technol Ther. 2014 Oct;16(10):679-87
pubmed: 25036533
Diabetes Technol Ther. 2020 Apr;22(4):330-336
pubmed: 31859529
Diabetes Care. 2022 Aug 1;45(8):1833-1840
pubmed: 35679098
Diabetes. 1999 Jan;48(1):86-93
pubmed: 9892226
Children (Basel). 2021 Jan 10;8(1):
pubmed: 33435250
Am J Physiol Renal Physiol. 2009 Dec;297(6):F1647-55
pubmed: 19776173
J Clin Endocrinol Metab. 2017 Feb 01;102(2):407-415
pubmed: 27732328
J Clin Endocrinol Metab. 2000 Nov;85(11):4053-9
pubmed: 11095432
Diabet Med. 2008 Feb;25(2):152-6
pubmed: 18201212
Curr Atheroscler Rep. 2022 Nov;24(11):867-884
pubmed: 36044100
Mol Metab. 2021 Apr;46:101102
pubmed: 33068776
Pediatr Diabetes. 2012 Aug;13(5):369-75
pubmed: 22369102
J Hepatol. 2016 Feb;64(2):399-408
pubmed: 26394161
N Engl J Med. 2022 Dec 15;387(24):2245-2257
pubmed: 36322838
JAMA. 2021 Aug 24;326(8):717-727
pubmed: 34427600
Diabetologia. 2020 Apr;63(4):683-691
pubmed: 31897525
Annu Rev Med. 2022 Jan 27;73:501-515
pubmed: 35084995
Gastroenterology. 2004 Aug;127(2):546-58
pubmed: 15300587
Pediatr Diabetes. 2022 Nov;23(7):872-902
pubmed: 36161685
Endocrinology. 2009 Jun;150(6):2654-9
pubmed: 19264875
J Pediatr Gastroenterol Nutr. 2005 Jul;41(1):94-8
pubmed: 15990637
Diabetes Obes Metab. 2018 Jan;20(1):215-218
pubmed: 28681988
Neurogastroenterol Motil. 2009 Sep;21(9):978-e78
pubmed: 19453518
Diabetes Care. 2021 Jan;44(Suppl 1):S100-S110
pubmed: 33298419
Am J Physiol. 1999 May;276(5):R1541-4
pubmed: 10233049
Diabetes Care. 2013 Jun;36(6):1777-8
pubmed: 23704679
Diabetes Care. 2021 Mar;44(3):817-825
pubmed: 33436401
Diabetes. 2019 Aug;68(8):1670-1680
pubmed: 31178433
Diabetologia. 2022 Dec;65(12):1925-1966
pubmed: 36151309
Obesity (Silver Spring). 2012 Feb;20(2):364-70
pubmed: 22076596
J Endocrinol. 1995 Oct;147(1):25-31
pubmed: 7490533
N Engl J Med. 2012 Jun 14;366(24):2247-56
pubmed: 22540912
Lancet. 2014 Dec 20;384(9961):2228-34
pubmed: 25220191
Diabetes Care. 2022 Jan 1;45(Suppl 1):S208-S231
pubmed: 34964865
Pediatr Obes. 2021 Aug;16(8):e12778
pubmed: 33634589
Endocrinology. 1999 Jan;140(1):244-50
pubmed: 9886831
Diabetes Care. 2023 Jan 1;46(Suppl 1):S140-S157
pubmed: 36507650
Nat Rev Nephrol. 2023 Mar;19(3):168-184
pubmed: 36316388
Diabetes Care. 2016 Mar;39(3):323-9
pubmed: 26908928
N Engl J Med. 2021 Nov 18;385(21):2016
pubmed: 34788520
Clin Ther. 2009 Apr;31(4):806-15
pubmed: 19446153
N Engl J Med. 2022 Oct 20;387(16):1530-1531
pubmed: 36260805
J Clin Invest. 2014 Oct;124(10):4473-88
pubmed: 25202980
Pediatr Diabetes. 2018 Oct;19 Suppl 27:28-46
pubmed: 29999228
N Engl J Med. 2019 Aug 15;381(7):637-646
pubmed: 31034184
N Engl J Med. 2017 Aug 31;377(9):839-848
pubmed: 28854085
Scand J Gastroenterol. 1996 Jul;31(7):665-70
pubmed: 8819215
Eur J Pharmacol. 2020 Jan 15;867:172844
pubmed: 31811859
N Engl J Med. 2021 Mar 25;384(12):1113-1124
pubmed: 33185364
N Engl J Med. 1974 Sep 12;291(11):544-7
pubmed: 4604408
Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785
pubmed: 31422062
Cell Metab. 2016 Mar 8;23(3):541-6
pubmed: 26876561
Pharmacol Ther. 2007 Mar;113(3):546-93
pubmed: 17306374
Lancet Diabetes Endocrinol. 2018 Aug;6(8):605-617
pubmed: 29910024
Endocrine. 2020 Jun;68(3):518-525
pubmed: 32103407
Front Endocrinol (Lausanne). 2021 Oct 21;12:738848
pubmed: 34745006
Mol Metab. 2019 Dec;30:72-130
pubmed: 31767182
Pediatr Diabetes. 2021 Sep;22(6):861-871
pubmed: 33978986
Pediatr Diabetes. 2015 Feb;16(1):39-47
pubmed: 24450390
Diabetes Care. 2016 May;39(5):823-9
pubmed: 27006511
Obesity (Silver Spring). 2022 May;30(5):1105-1115
pubmed: 35403350
N Engl J Med. 2020 May 28;382(22):2117-2128
pubmed: 32233338
Front Endocrinol (Lausanne). 2021 Aug 23;12:721135
pubmed: 34497589
Int J Obes Relat Metab Disord. 2003 Mar;27(3):313-8
pubmed: 12629557
Diabetes. 2009 Jun;58(6):1312-20
pubmed: 19228811
Mol Metab. 2022 Mar;57:101351
pubmed: 34626851
BMC Neurosci. 2012 Mar 23;13:33
pubmed: 22443187
Diabetes. 2010 Jul;59(7):1765-70
pubmed: 20150286
PLoS One. 2014 Oct 27;9(10):e109702
pubmed: 25347846
Diabetologia. 2022 Aug;65(8):1251-1261
pubmed: 35579691
J Diabetes. 2017 Aug;9(8):800-809
pubmed: 28332301